Mobile clinics & health schemes................Incredible India

Yesterday I was reading an article on Top drug makers in US pledging $80 Billion for providing drugs over to people in US in coming decade, what I was thinking why don’t drug companies and state government collaborate to start Mobile clinics and community health plan. There are some organizations in down south which are catering to the need of rural and urban India as in Karnataka, and there was one company started by budding entrepreneurs in Rajasthan but these people working in rural parts of Rajasthan were not able to continue for more than a year for lack of funds. Why don’t we take an initiative to have these mobile hospitals and health plan or rather community plan for the lower middle class and for those living below the poverty line?

Wockhardt sometime back started mobile clinic in and around Aurangabad district of Maharashtra. Why don’t more companies come out in open and take this initiative and we all should be part of the movement to make India the best place to live.

Because this movement will not only cater to the requirement of medicines for lower income group but at the end of the day will lead to more job opportunities for skilled and non skilled people. Let’s pledge for "Incredible India".

Big Pharma going for generic/biosimilar Acquisitions............................

There are many success stories of generic companies becoming a billion dollar company in a short span of time, over the past 20 years we have seen that many generics companies became public in duration of 7-9 years, it’s a great achievement of these companies.

As the competition is becoming tough day by day between the innovator companies and the generics, I feel that big daddy's such as Pfizer, GSK, J&J, and Merck will soon perhaps in coming quater or year/next decade will strategise their deal towards acquiring medium to average size (200-800M revenue) generic or bio similar companies.

What do you people feel about it, share your thoughts.......

Cipla story.....................

Cipla was founded in year 1935 as The Chemical, Industrial & Pharmaceutical Laboratories. It is a prominent Indian pharmaceutical company, which is market leader in respiratory segment with its brand Asthalin, cardiovascular disease, arthritis, diabetes, weight control, depression and in recent past has diversified into AIDS and HIN1 treatment. In early 1980's it persuaded than congress government to give relaxation in Indian patent law so that home grown generic companies could meet the domestic market demand, this helped many prescription based generic companies to expand internally and in global scenario. Cipla through this reform now has its global presence in more than 180 countries.

Cipla this decade after GATT agreement follow up in Indian pharma scenario in year 2005 has shifted it focus on manufacturing generic version of drugs used for life threatening and pandemic diseases, In this scenario as its making life saving drugs cheaper version in one fourth of their original price it gets support of NGO's all over the world and world health organization, so that the originator companies cant pin point, I am very sure within 1 year it will launch its own generic version for treatment of H1N5.

At present Cipla has revenue worth approximately USD100 Billon and you can perhaps say it’s a highly profitable company with so called humanity touch , I think case studies should be prepared for how this small company went on to become top generic player in India and world with its very unique business model.

Hoover's free day out .......

Sometime around 1 year back I had chance to use One source data base in my previous organization and Hoovers was accessible to some privileged people in investment research, today on this day 17th of June 2009, I got an email from Hoovers saying that I can access their database till 5:30 PST, 17th June 2009..........I came from office at around 3:00 AM (IST), 18th June 2009 and I wanted to explore Hoovers, what I found is that Hoovers is more comprehensive than one source as it has industry wise in-depth segmentation.....I have become an ardent fan of Hoover database............................what about you all, when are you going to explore it :)

Dr Reddy's and GSK alliance...................

As stated by me on 14th June blog about Reddy's alliance with some european pharma giants, the news is Dr Reddy's and GSK signed a deal which gives GSK exclusive access to Dr. Reddy's portfolio and pipeline of more than 100 branded pharmaceuticals in segments including cardiovascular, diabetes, oncology, gastroenterology and pain management, wherein these products will be manufactured by Dr. Reddy's and licensed and supplied by Glaxo in countries in Africa, Middle East, Asia Pacific and Latin America. In certain markets, products will be co-marketed by GlaxoSmithKline and Dr. Reddy's.

After Pfizer in US it is Glaxo in Europe which is aggresively closing deals.......................

After Ranbaxy Labs its Wockhradt in news ....

After Ranbaxy Labs sales in 2008, there is one more big M & A for year 2009, i.e. sale of Wockhardt biotechnology and veterinary division, According to some reports US drug major Pfizer is reportedly in an advanced stage of talks with Wockhardt to acquire its biotechnology and veterinary divisions, the deal, which could value Wockhardt's comparatively smaller businesses is of worth around Rs 1.2bn.

Indian Pharma Inc.......................

Yesterday I was reading about big pharmaceuticals eying for Indian generic players.....I know that at this time Indian generic or prescription drug market is vulnerable, there was news in march that GSK was first eying on Nicholas Piramal and then it went on closing deal with Shanta Biotech.....and later Wockhardt hospitals being acquired by Apollo group.......there are many ventures to come such as Reddy's alliance with European pharma giants, Biocon licensing with top 5 American pharma giants.....we have more to see, its just the beginning for India Inc..........I feel that Indian companies should wait for some more time and go for higher value deal than Ranbaxy labs , 10 time more than Ranbaxy-Diiachi deal.........................................What do you people say?

Two sides of coin.......MERCK Inc.

Merck at one side has made a $185 Million deal with Xenon pharmaceutical Inc to discover, develop novel small molecule candidates for the potential treatment of cardiovascular disease and on the other side on the very same day it announced that it is going to shed around 16,000 jobs as it is combining its operations with its rival Schering-Plough.......Merck was once considered one of the best pharmaceutical companies to work with and there were many white papers written on this company history.........its was considered as company with humanity touch :)........what will you say about it now?